Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories
Cryoport (NASDAQ: CYRX) has announced the launch of MVE Biological Solutions' High-Efficiency 800 C (HE 800 C), a new cryogenic freezer designed for fertility clinics, biorepositories, and clinical laboratories. The device offers ultra-cold storage at -190°C with a capacity to store over 22,000 ½cc straws in a compact, space-efficient design.
The HE 800 C features compatibility with SUC-1 inventory management systems for streamlined sample organization and retrieval. The freezer combines ergonomic features for easier sample handling, reducing strain on laboratory personnel while maintaining consistent performance in preserving sensitive biological materials.
Cryoport (NASDAQ: CYRX) ha annunciato il lancio del High-Efficiency 800 C (HE 800 C) di MVE Biological Solutions, un nuovo congelatore criogenico progettato per cliniche di fertilità, biorepository e laboratori clinici. Il dispositivo offre una conservazione ultra-fredda a -190°C con una capacità di stoccare oltre 22.000 provette da ½cc in un design compatto e salvaspazio.
Il HE 800 C è compatibile con i sistemi di gestione dell'inventario SUC-1 per una migliore organizzazione e recupero dei campioni. Il congelatore combina caratteristiche ergonomiche per facilitare la manipolazione dei campioni, riducendo lo sforzo per il personale di laboratorio, mantenendo al contempo prestazioni costanti nella conservazione di materiali biologici sensibili.
Cryoport (NASDAQ: CYRX) ha anunciado el lanzamiento del High-Efficiency 800 C (HE 800 C) de MVE Biological Solutions, un nuevo congelador criogénico diseñado para clínicas de fertilidad, biobancos y laboratorios clínicos. El dispositivo ofrece almacenamiento a ultra-bajo temperatura a -190°C con una capacidad para almacenar más de 22,000 pajillas de ½cc en un diseño compacto y eficiente en espacio.
El HE 800 C es compatible con los sistemas de gestión de inventario SUC-1 para una organización y recuperación de muestras más fluida. El congelador combina características ergonómicas para facilitar el manejo de muestras, reduciendo la carga para el personal del laboratorio mientras mantiene un rendimiento constante en la preservación de materiales biológicos sensibles.
크라이오포트 (NASDAQ: CYRX)는 MVE Biological Solutions의 High-Efficiency 800 C (HE 800 C)라는 새로운 극저온 냉동고를 출시했다고 발표했습니다. 이 장치는 난임 클리닉, 생물 저장소 및 임상 실험실을 위해 설계되었으며, -190°C에서 초저온 저장을 제공하며 ½cc 스트로를 22,000개 이상 저장할 수 있는 컴팩트하고 공간 효율적인 디자인을 가지고 있습니다.
HE 800 C는 샘플 조직 및 검색을 원활하게 하기 위해 SUC-1 재고 관리 시스템과의 호환성을 특징으로 합니다. 이 냉동고는 샘플 취급을 용이하게 하기 위한 인체공학적 기능을 결합하여 실험실 직원의 부담을 줄이면서 민감한 생물학적 물질을 보존하는 데 일관된 성능을 유지합니다.
Cryoport (NASDAQ: CYRX) a annoncé le lancement du High-Efficiency 800 C (HE 800 C) de MVE Biological Solutions, un nouveau congélateur cryogénique conçu pour les cliniques de fertilité, les biobanques et les laboratoires cliniques. L'appareil offre un stockage ultra-froid à -190°C avec une capacité de stockage de plus de 22 000 paillettes de ½cc dans un design compact et optimisé pour l'espace.
Le HE 800 C est compatible avec les systèmes de gestion des stocks SUC-1 pour une organisation et un accès simplifiés des échantillons. Le congélateur combine des caractéristiques ergonomiques pour faciliter la manipulation des échantillons, réduisant ainsi la fatigue du personnel de laboratoire tout en maintenant des performances constantes dans la préservation de matériaux biologiques sensibles.
Cryoport (NASDAQ: CYRX) hat die Einführung des High-Efficiency 800 C (HE 800 C) von MVE Biological Solutions angekündigt, einem neuen kryogenen Gefrierschrank, der für Fertilitätskliniken, Biorepositories und klinische Labore konzipiert ist. Das Gerät bietet eine ultrakalte Lagerung bei -190 °C mit einer Kapazität von über 22.000 ½cc Röhrchen in einem kompakten und platzsparenden Design.
Der HE 800 C bietet Kompatibilität mit den Inventarverwaltungssystemen SUC-1 für eine optimierte Organisation und Abruf von Proben. Der Gefrierschrank kombiniert ergonomische Merkmale für eine einfachere Handhabung von Proben, wodurch die Belastung des Laborpersonals verringert wird, während eine konsistente Leistung bei der Erhaltung empfindlicher biologischer Materialien gewährleistet bleibt.
- Launch of new high-capacity cryogenic storage product expanding product portfolio
- Product offers competitive advantages: high storage density and space efficiency
- Integration with existing inventory management systems enhances market appeal
- None.
Insights
Cryoport's launch of the MVE Biological Solutions' High-Efficiency 800 C cryogenic freezer represents an incremental expansion of its specialized storage solutions portfolio. This addition to their existing HE Series targets fertility clinics, biorepositories, and clinical laboratories with specific features designed to address their operational needs.
The technical specifications are noteworthy from a practical standpoint. The unit provides storage capacity for over 22,000 ½cc straws at ultra-low temperatures (-190°C), essential for maintaining biological sample integrity. The emphasis on ergonomic design addresses a significant pain point in laboratory settings where technicians must frequently access stored materials.
Compatibility with SUC-1 inventory management systems indicates a focus on workflow efficiency and sample security. This integration capability is particularly valuable for facilities managing large sample volumes where organization and quick retrieval are operational priorities.
From a product development perspective, this launch represents evolutionary rather than revolutionary advancement in Cryoport's portfolio. While the announcement lacks financial projections or pricing information, specialized cryogenic equipment typically commands premium pricing in the life sciences market.
The product appears to be a logical extension of Cryoport's existing technology platform, addressing specific user needs in established market segments. Without additional context on market size or expected adoption rates, this launch likely represents a modest enhancement to Cryoport's competitive positioning rather than a transformative development for the company's financial performance.
"With the HE 800 C, we are delivering an unmatched cryogenic storage solution that balances high-capacity preservation with a practical and user-friendly, space-efficient design," said Jerrell Shelton, CEO, Cryoport. "With the ability to store over 22,000 ½cc straws, the HE 800 C offers ultra-cold, high-density storage while optimizing workflow, enabling clinics and laboratories to maximize their available space without compromising the security of these critical life sciences materials."
Building on the trusted reputation of the HE Series, the HE 800 C provides ultra-low temperature storage at -190°C, ensuring the integrity of sensitive biological materials. The HE 800 C is compatible with SUC-1 inventory management systems, which enables easy identification and retrieval of samples to streamline sample organization and retrieval. Its superior ergonomic design makes loading and retrieving samples more accessible, reducing strain on laboratory personnel.
"Reliability, efficiency and access are key in cryogenic storage, and the HE 800 C is designed to excel in these areas," added Mike Duich, President and CEO, MVE Biological Solutions. "The HE 800 C provides enhanced sample safety while making retrieval and organization more intuitive and efficient, ultimately allowing medical researchers and clinicians to focus on their work with confidence."
To learn more about the HE 800 C, please visit https://mvebio.com/our-products/life-science-freezers/he800c or reach out to marketing@mvebio.com.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to MVE Biological Solutions' High-Efficiency 800 C freezer, including its potential impact on revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoports-mve-biological-solutions-expands-high-efficiency-cryogenic-freezer-series-with-answer-to-evolving-needs-of-fertility-clinics-biorepositories-and-clinical-laboratories-302399517.html
SOURCE Cryoport, Inc.
FAQ
What is the storage capacity of Cryoport's new HE 800 C freezer?
What are the key features of CYRX's High-Efficiency 800 C freezer?
Which market segments is Cryoport targeting with the HE 800 C?
How does the new CYRX freezer improve laboratory workflow?
